Dollar General sees same-store sales gaining as much as 2.5% this fiscal year, up from guidance in March calling for an ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

British American Tobacco nudged up its annual sales growth target on Tuesday to 1%-2%, saying revenue in the first half was ahead of expectations and sales in the United States were picking up. The ...

Shares retreat, steel tariffs boost BlueScope; Opthea’s director exodus; Soul Patts, Brickworks to merge; oil up 2pc; iron ...

Discount retailer Ollie's Bargain Outlet Holdings beat estimates for the first quarter on Tuesday and lifted its sales ...

People are spending more at Dollar General. In part, that's thanks to shoppers trading down from more expensive stores.

Brown-Forman forecast a decline in annual revenue and profit on Thursday, as the Jack Daniel's maker navigates soft consumer ...

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

However, there is optimism surrounding the AI company, whose strong full-year guidance for 2025 sees a sales forecast between $3.74 billion and $3.76 billion, topping average estimates of $3.52 ...

The median forecasts in this calendar come from surveys of economists conducted by Dow Jones Newswires and The Wall Street Journal. All statistics in this calendar are in expressed in nominal ...